PamDx, tradename of PamGene International B.V., has announced it has secured $15.3 million in new investment capital. This funding round marks a significant milestone for the company, which is a leader in kinase activity profiling, providing innovative solutions that support biomarker and drug development research, and in-vitro diagnostics.
The company's proprietary technology measures functional kinase enzyme activity in a near-physiological context, offering high sensitivity, broad kinome coverage, and compatibility with diverse sample types. Through its PamDx brand and IOpener® services, the company is expanding into in-vitro diagnostics, aiming to translate kinase activity profiling into clinically actionable information for immunotherapy patient treatment selection. PamDx's research use only product portfolio includes the PamStation platform, PamChip arrays, reagent kits, and BioNavigator software, which transforms complex signaling data into meaningful biological insights.
The newly raised capital will be instrumental in accelerating PamDx's strategic growth initiatives. The funds are planned to support the continued development and commercialization of its innovative solutions, particularly its expansion into the in-vitro diagnostics market. This investment will enable PamDx to further its mission of providing valuable tools across the full spectrum, from early discovery research to clinical development and ultimately diagnostics.
Looking ahead, PamDx aims to solidify its position as a key player in kinase activity profiling. The company is focused on leveraging this investment to enhance its technological capabilities and broaden its impact, ultimately contributing to improved patient treatment selection, especially within the field of immunotherapy.
.png&w=3840&q=75)
